Daniela Oniciu

Daniela Oniciu

Geen lopende functies

Health Technology
Consumer Services

Profiel

Daniela Carmen Oniciu is the founder of Creative Pharma Advisors LLC.
She worked as an Associate Director-Chemistry at Pfizer Inc. from 2004 to 2008.
Prior to that, she was a Senior Director-Chemical Research & Development at Esperion Therapeutics, Inc. from 2001 to 2004.
From 2005 to 2014, she held the position of Senior Director-Chemistry at ABIONYX Pharma SA. Later, she served as the Vice President-Preclinical Research & Development at Gemphire Therapeutics, Inc. from 2014 to 2018.
In addition to her former jobs, she also worked as the Chief Operating Officer at BioSavita, Inc. and as the Head-Research & Development at Ocuphire Pharma, Inc. Dr. Oniciu obtained her graduate and doctorate degrees from Politehnica University of Bucharest.

Eerdere bekende functies van Daniela Oniciu

BedrijvenFunctieEinde
OCUPHIRE PHARMA, INC. Hoofd Techniek/Wetenschap/O&O 31-12-2023
NEUROBO PHARMACEUTICALS, INC. Hoofd Techniek/Wetenschap/O&O 01-11-2018
ABIONYX PHARMA Corporate Officer/Principal 01-02-2014
PFIZER, INC. Corporate Officer/Principal 01-02-2008
ESPERION THERAPEUTICS, INC. Corporate Officer/Principal 01-01-2004
Ervaring van Daniela Oniciu in detail bekijken

Opleiding van Daniela Oniciu

Politehnica University of Bucharest Doctorate Degree

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Ervaring van Daniela Oniciu in detail bekijken

Connecties

100 +

Eerstegraads connecties

8

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Persoonlijk netwerk weergeven

Verwante bedrijven

Beursgenoteerde bedrijven4
PFIZER, INC.

Health Technology

ESPERION THERAPEUTICS, INC.

Health Technology

ABIONYX PHARMA

Health Technology

OCUPHIRE PHARMA, INC.

Health Technology

Bedrijven in privébezit3

Health Technology

Health Technology

Creative Pharma Advisors LLC

Zie bedrijfsconnecties
  1. Beurs
  2. Insiders
  3. Daniela Oniciu
-40 % Aanbod van beperkte duur: onze abonnementen leiden je naar de beste beleggingen van morgen.
PROFITEER NU